- Home
- ADSE vs PSNL Comparison
ADSE vs PSNL Comparison
Compare ADSE & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | PSNL |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | Ireland | United States |
| Employees | 302 | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.0M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ADSE | PSNL |
|---|---|---|
| Price | $11.40 | $10.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 2.5K | ★ 3.0M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $549.86 | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.89 | $3.84 |
| 52 Week High | $13.90 | $12.53 |
Technical Indicators
Market Signals| Indicator | ADSE | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 60.67 |
| Support Level | $11.20 | $7.26 |
| Resistance Level | $12.01 | $11.28 |
| Average True Range (ATR) | 0.40 | 0.95 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 62.28 | 37.83 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.